Simron Singh, MD, MPH, FRCPC
Medical Oncologist
Sunnybrook Health Science Centre
Toronto, Canada
Simron Singh, MD, MPH, FRCPC, is a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute in Toronto, Canada. He helped establish a patient-centered, multidisciplinary, specialized neuroendocrine clinic at the Sunnybrook Odette Cancer Centre (one of the first of its kind in the region. He is involved in numerous activities in the care of neuroendocrine cancer patients including the role of Ki-67 as a prognostic marker, and the utilization of health care resources in the diagnosis and treatment of neuroendocrine tumor patients. His research interests also include population health and cancer care utilization discrepancies.
Dr. Singh serves on the Board of Directors of the North American Neuroendocrine Tumor Society, NANETS, as well as on the NET Symposium Program and Membership and Diversity Committees. He is also active in CommNETs, the Commonwealth Neuroendocrine Tumor research collaborative.
Resources:
Dr. Singh at Sunnybrook Research Institute: https://sunnybrook.ca/research/team/member.asp?t=38&m=442&page=902
The Susan Leslie Clinic for Neuroendocrine Tumor Program at Sunnybrook: https://sunnybrook.ca/content/?page=neuroendocrine-tumour-cancer
NANETS, the North American Neuroendocrine Tumor Society, https://nanets.net/
CommNETs, the Commonwealth Neuroendocrine Tumor research collaborative, https://gicancer.org.au/health-professionals/commnets/
Videos featuring Dr. Singh:
- Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial, https://vimeo.com/152836672
- Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience, https://vimeo.com/293018529
Selected articles: https://sunnybrook.ca/research/team/member.asp?t=38&m=442&page=902
- Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results from the First Global Survey of Patients with NETs, https://www.carcinoid.org/wp-content/uploads/2016/06/Patient-Reported-Burden-of-a-Neuroendocrine-Tumor-NET-Diagnosis_Results-from-the-First-Global-Survey-of-Patients-with-NETs-JGO-2016-Singh-JGO.2016.002980.pdf
- Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines, https://www.carcinoid.org/wp-content/uploads/2020/10/Commnet-NANETS-Lung-Guidelines-2020.pdf
- Canadian Neuroendocrine Tumor Guidelines, http://www.cnetscanada.org/patients-caregivers/resources/438-2/
- A tapestry of clinical trials: High-impact findings: greater effectiveness, more precision, less harm and cost-conscious—this is what the cancer care of tomorrow looks like, emerging from the clinical trials of today (SRI Magazine, 2016)
- Stomach, pancreatic and other upper GI cancers: new findings are providing much-needed treatment guidance: Upper gastrointestinal cancers are under-studied in Canada. Given their grim outlook—at best, intrusive; at worst, fatal—it’s a void begging to be filled (SRI Magazine, 2016)
- Are recent immigrants to Ontario healthy? Data dig unearths unexpected findings (SRI Magazine, 2016)
Social Media:
NANETS
Facebook, https://www.facebook.com/NANETS/
Twitter, @NANETS1, https://twitter.com/NANETS1
LinkedIn, https://www.linkedin.com/company/nanets/
Sunnybrook Health Sciences Centre
Facebook, https://www.facebook.com/SunnybrookHSC/
Twitter, @Sunnybrook, https://www.twitter.com/Sunnybrook
YouTube, https://www.youtube.com/user/SunnybrookMedia?sub_confirmation=1
Instagram, https://www.instagram.com/sunnybrookhsc/
